Company Description
Waldencast plc operates in the beauty and wellness industry.
It engages in developing, acquiring, accelerating, and scaling various brands. The company provides cosmetic, over-the-counter, and prescription products under the Obagi Medical, Obagi Clinical, and Obagi Professional brands; and a Skintrinsiq device for use in facial treatments that is used by physicians' offices, spas, and aestheticians.
It also offers clean makeup products under the Milk Makeup brand. The company sells its products to dermatologists, plastic surgeons, and other physicians who focuses on aesthetic and therapeutic skincare, including physicians on site at medical spas, through its direct sales force, as well as through distribution partners.
Waldencast plc was incorporated in 2020 and is headquartered in White Plains, New York.
| Country | United States |
| Founded | 1988 |
| IPO Date | Mar 16, 2021 |
| Industry | Software - Application |
| Sector | Technology |
| Employees | 284 |
| CEO | Michel Brousset |
Contact Details
Address: 10 Bank Street, Suite 560 White Plains, New York 10606 United States | |
| Phone | (917) 546-6828 |
| Website | waldencast.com |
Stock Details
| Ticker Symbol | WALD |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $10.00 |
| CIK Code | 0001840199 |
| CUSIP Number | G9503X103 |
| ISIN Number | JE00BPG99318 |
| SIC Code | 2844 |
Key Executives
| Name | Position |
|---|---|
| Felipe Dutra | Executive Chairman |
| Michel Brousset | Founder, Chief Executive Officer and Director |
| Hind Sebti | Founder and Chief Growth Officer |
| Manuel Manfredi | Chief Financial Officer |
| Elisabeth Milan | General Counsel |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 13, 2024 | 6-K | Report of foreign issuer |
| Apr 30, 2024 | 6-K | Report of foreign issuer |
| Apr 30, 2024 | 20-F | Annual and transition report of foreign private issuers |
| Mar 25, 2024 | 6-K | Report of foreign issuer |
| Mar 21, 2024 | 6-K | Report of foreign issuer |
| Mar 21, 2024 | 6-K | Report of foreign issuer |
| Feb 26, 2024 | 6-K | Report of foreign issuer |
| Feb 9, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Feb 1, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Jan 31, 2024 | 6-K | Report of foreign issuer |